Rxo (RXO) Liabilities and Shareholders Equity (2021 - 2026)

Rxo (RXO) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $3.3 billion the latest figure, recorded in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $3.3 billion, down 1.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.9 billion (up 8.59% YoY), and the FY2025 annual result was $3.3 billion, down 4.01% from the prior year.
• Liabilities and Shareholders Equity was $3.3 billion for Q1 2026 at Rxo, roughly flat from $3.3 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $3.4 billion in Q4 2024 and troughed at $1.8 billion in Q1 2024.
• Average Liabilities and Shareholders Equity over 5 years is $2.6 billion, with a median of $2.2 billion recorded in 2022.
• Year-over-year, Liabilities and Shareholders Equity decreased 13.01% in 2023 and surged 87.07% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $2.0 billion in 2022, then dropped by 10.14% to $1.8 billion in 2023, then soared by 87.07% to $3.4 billion in 2024, then retreated by 4.01% to $3.3 billion in 2025, then slipped by 0.27% to $3.3 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $3.3 billion in Q1 2026, $3.3 billion in Q4 2025, and $3.2 billion in Q3 2025.